-
![Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide](/abs-image/US/2016/12/13/US09518058B2/abs.jpg.150x150.jpg)
1.发明授权Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide 有权制备N，N-二环丙基-4-（1,5-二甲基-1H-吡唑-3-基氨基）-6-乙基-1-甲基-1,6-二氢咪唑并[4,5-d]吡咯的方法 [2,3-b]吡啶-7-甲酰胺公开(公告)号：US09518058B2
公开(公告)日：2016-12-13
申请号：US14914330
申请日：2014-08-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Martin D. Eastgate , Gregory L. Beutner , Benjamin Cohen , Nicolas Cuniere , Lopa V. Desai , Monica Fitzgerald , Qi Gao , Michael Bryan Hay , Michael Joseph Lawler , Paul C. Lobben , Christopher S. Regens , Thorsten Rosner , Neil Strotman , Carolyn S. Wei , Yi Xiao , Bin Zheng , Keming Zhu
IPC: C07D471/14 , C07D207/42 , C07D403/04 , C07D231/16
CPC classification number: C07D471/14 , C07D207/42 , C07D231/16 , C07D403/04
Abstract: The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.
-
![Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine](/abs-image/US/2015/10/13/US09156812B2/abs.jpg.150x150.jpg)
2.发明授权Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine 有权6 - [（4S）-2-甲基-4-（2-萘基）-1,2,3,4-四氢异喹啉-7-基]哒嗪-3-胺的结晶形式公开(公告)号：US09156812B2
公开(公告)日：2015-10-13
申请号：US13845919
申请日：2013-03-18
Inventor： Jun Qiu , Qi Gao , Shuang Liu , Min Hu , Yuh-Lin Allen Yang , Matthew Isherwood , Rasidul Amin
IPC: A61K31/435 , A61K31/495 , A61K31/501 , C07D401/04
CPC classification number: A61K31/501 , A61K31/435 , A61K31/495 , C07D401/04
Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.
Abstract translation: 本公开内容通常涉及6 - [（4S）-2-甲基-4-（萘基）-1,2,3,4-四氢异喹啉-7-基]哒嗪-3-胺的结晶形式。 本公开还通常涉及包含结晶形式的药物组合物，以及在治疗抑郁症和其它病症中使用结晶形式的方法以及获得这种结晶形式的方法。
-
Patent Agency Ranking
![Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof](/abs-image/US/2015/11/03/US09173879B2/abs.jpg.150x150.jpg)
3.发明授权Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof 有权（S）-7 - （[1,2,4]三唑并[1,5-a]吡啶-6-基）-4-（3,4-二氯苯基）-1,2,3,4-四氢异喹啉的结晶形式 四氢异喹啉及其用途公开(公告)号：US09173879B2
公开(公告)日：2015-11-03
申请号：US14466009
申请日：2014-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Chenkou Wei , Victor W. Rosso , Qi Gao
IPC: C07D471/04 , A61K31/495 , A61K31/4725 , A61K31/437 , A61K31/438 , A61K45/06
CPC classification number: A61K31/4725 , A61K31/437 , A61K31/438 , A61K31/495 , A61K45/06 , C07D471/04
Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
Abstract translation: 在本发明中描述了新的[1,2,4]三唑并[1,5-a]吡啶基-6-基取代的四氢异喹啉。 这些化合物和结晶形式SA1和N-2用于治疗各种神经和生理疾病。 制备这些化合物和结晶形式SA-1和N-2的方法也在本发明中描述。
-
![CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF](/abs-image/US/2014/12/11/US20140364441A1/abs.jpg.150x150.jpg)
4.发明申请CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF 有权（S）-7 - （[1,2,4]三唑并[1,5-a]吡啶-6-基）-4-（3,4-二氯苯基）-1,2,3,4-四氢异喹啉的晶体形式 四氢喹诺酮及其用途公开(公告)号：US20140364441A1
公开(公告)日：2014-12-11
申请号：US14466009
申请日：2014-08-22
Applicant: Bristol-Myers Squibb Company
Inventor： Chenkou Wei , Victor W. Rosso , Qi Gao
IPC: A61K31/4725 , A61K45/06 , C07D471/04
CPC classification number: A61K31/4725 , A61K31/437 , A61K31/438 , A61K31/495 , A61K45/06 , C07D471/04
Abstract: Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.
Abstract translation: 在本发明中描述了新的[1,2,4]三唑并[1,5-a]吡啶基-6-基取代的四氢异喹啉。 这些化合物和结晶形式SA1和N-2用于治疗各种神经和生理疾病。 制备这些化合物和结晶形式SA-1和N-2的方法也在本发明中描述。
-
![Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine](/abs-image/US/2016/11/22/US09498476B2/abs.jpg.150x150.jpg)
公开(公告)号：US09498476B2
公开(公告)日：2016-11-22
申请号：US14841024
申请日：2015-08-31
Inventor： Jun Qiu , Qi Gao , Shuang Liu , Min Hu , Yuh-Lin Allen Yang , Matthew Isherwood , Rasidul Amin
IPC: A61K31/435 , A61K31/495 , A61K31/501 , C07D401/04
CPC classification number: A61K31/501 , A61K31/435 , A61K31/495 , C07D401/04
Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.
-
![PROCESS FOR THE PREPARATION OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-d]PYRROLO[2,3-b]PYRIDINE-7-CARBOXAMIDE](/abs-image/US/2016/08/11/US20160229854A1/abs.jpg.150x150.jpg)
6.发明申请PROCESS FOR THE PREPARATION OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-d]PYRROLO[2,3-b]PYRIDINE-7-CARBOXAMIDE 审中-公开制备N，N-二异丙基-4-（1,5-二甲基-1H-吡唑-3-基氨基）-6-乙基-1-甲基-1,6-二氢吲哚并[4,5-d]吡咯的方法 [2,3-b]吡啶-7-羧酰胺公开(公告)号：US20160229854A1
公开(公告)日：2016-08-11
申请号：US14914330
申请日：2014-08-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Martin D. Eastgate , Gregory L. Beutner , Benjamin Cohen , Nicolas Cuniere , Lopa V. Desai , Monica Fitzgerald , Qi Gao , Michael Bryan Hay , Michael Joseph Lawler , Paul C. Lobben , Christopher S. Regens , Thorsten Rosner , Neil Strotman , Carolyn S. Wei , Yi Xiao , Bin Zheng , Keming Zhu
IPC: C07D471/14 , C07D403/04 , C07D231/16 , C07D207/42
CPC classification number: C07D471/14 , C07D207/42 , C07D231/16 , C07D403/04
Abstract: The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.
Abstract translation: 本发明涉及一种合成N，N-二环丙基-4-（1,5-二甲基-1H-吡唑-3-基氨基）-6-乙基-1-甲基-1,6-二氢咪唑并[4,5 d]吡咯并[2,3-b]吡啶-7-甲酰胺，其化学式（I）化合物（I）目前正在临床试验中用于治疗骨髓增生性疾病，如多发性红血球病，血小板减少症和原发性骨髓纤维化。
-
![CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE](/abs-image/US/2015/12/24/US20150366864A1/abs.jpg.150x150.jpg)
7.发明申请CRYSTALLINE FORM OF 6-[(4S)-2-METHYL-4-(2-NAPHTHYL)-1,2,3,4-TETRAHYDROISOQUINOLIN-7-YL]PYRIDAZIN-3-AMINE 有权6 - [（4S）-2-甲基-4-（2-萘基）-1,2,3,4-四氢喹啉-7-YL]吡啶-3-胺的晶体形式公开(公告)号：US20150366864A1
公开(公告)日：2015-12-24
申请号：US14841024
申请日：2015-08-31
Inventor： Jun Qiu , Qi Gao , Shuang Liu , Min Hu , Yuh-Lin Allen Yang , Matthew Isherwood , Rasidul Amin
IPC: A61K31/501
CPC classification number: A61K31/501 , A61K31/435 , A61K31/495 , C07D401/04
Abstract: The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form.
Abstract translation: 本公开内容通常涉及6 - [（4S）-2-甲基-4-（萘基）-1,2,3,4-四氢异喹啉-7-基]哒嗪-3-胺的结晶形式。 本公开还通常涉及包含结晶形式的药物组合物，以及在治疗抑郁症和其它病症中使用结晶形式的方法以及获得这种结晶形式的方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.016 seconds)
